Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus
Open Access
- 1 March 2002
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 9 (6) , 363-371
- https://doi.org/10.1038/sj.gt.3301663
Abstract
The highly viscous secretions lining the upper airways and bronchi of cystic fibrosis (CF) patients may pose a significant barrier to successful gene therapy of the lung. In this report we examined the influence of CF mucus components (albumin, DNA, mucin and phospholipids) on the gene transfection activity of cationic DOTAP-based lipoplexes and pegylated GL67-based lipoplexes which previously have been used in CF clinical studies. Upon exposure of the cationic DOTAP:DOPE lipoplexes to either albumin, linear DNA or mucin (at concentration ratios expected to occur in vivo) a significant decrease in gene transfection activity was observed. This was primarily due to aggregation of the lipoplexes. However, exposure of pegylated GL67 lipoplexes to the same components did not affect their gene transfection activity. Indeed, it was determined that CF mucus components did not interact significantly with these pegylated GL67 lipoplexes. These results suggest that charge shielding of cationic gene carriers with pEG may favor their physicochemical stability in CF mucus and thereby aid in preserving their transfection activity.Keywords
This publication has 27 references indexed in Scilit:
- Gene therapy for cystic fibrosisThe Journal of Gene Medicine, 2001
- Cystic Fibrosis Gene Therapy Trials and TribulationsMolecular Therapy, 2000
- Enhancement of Dendrimer-Mediated Transfection Using Synthetic Lung Surfactant Exosurf Neonatal in VitroBiochemical and Biophysical Research Communications, 1999
- Lipoplex size is a major determinant of in vitro lipofection efficiencyGene Therapy, 1999
- The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epitheliumGene Therapy, 1999
- Status of gene therapy for cystic fibrosis lung diseaseJournal of Clinical Investigation, 1999
- Surfactant Inhibits Cationic Liposome-Mediated Gene TransferHuman Gene Therapy, 1997
- A Concentrated and Stable Aerosol Formulation of Cationic Lipid:DNA Complexes Giving High-Level Gene Expression in Mouse LungHuman Gene Therapy, 1997
- Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosisGene Therapy, 1997
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976